The role of docetaxel based therapy for prostate cancer in the era of targeted medicine: Review article

International Journal of Urology

Volumn 17, Issue 3, 2010, Pages 228-240

  Sonpavde, Guru ^a,b   Sternberg, Cora N ^c  

^a Texas Oncology ^*  (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Biological agents; Castration resistant prostate cancer; Docetaxel; Metastatic

Indexed keywords

ABIRATERONE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CANCER VACCINE; CELECOXIB; CIXUTUMUMAB; DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMC 3 G3; INSULIN LIKE GROWTH FACTOR 1 MONOCLONAL ANTIBODY; IPILIMUMAB; IXABEPILONE; KETOCONAZOLE; MDV 3100; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PROSTVAC; PROVENGE; SATRAPLATIN; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; WARFARIN; XRP 6258; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ALOPECIA; ANDROGEN DEPRIVATION THERAPY; ANOREXIA; BLOOD DISEASE; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHILL; CLINICAL TRIAL; COURSE EVALUATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; DYSPNEA; EARLY CANCER; EPIPHORA; EPISTAXIS; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; INFECTION; METABOLIC DISORDER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; OSTEOCLAST; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; STOMATITIS; TASTE DISORDER; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 77749285734     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02449.x     Document Type: Review

References (97)

1. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004 351 : 1502 1512.
2. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004 351 : 1513 1520.
3. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 1996 14 : 1756 1764.
4. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 1999 17 : 2506 2513.
5. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 2008 26 : 242 245.
6. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 2007 13: 6396 6403.
7. Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007 110 : 556 563.
8. Rosenberg JE, Ryan CJ, Weinberg VK et al. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J. Clin. Oncol. 2009 27 : 2772 2778.
9. Sternberg CN, Petrylak DP, Sartor O et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J. Clin. Oncol. 2009 27 : 5431 5438.
10. Armstrong AJ, Garrett-Mayer E, Ou Yang YC et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2007 25 : 3965 3970. (Pubitemid 47477275)
11. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J. Natl. Cancer Inst. 2006 98 : 516 521.
12. Hussain M, Goldman B, Tangen C et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 2009 27 : 2450 2456.
13. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 2008 26 : 1148 1159.
14. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J. Clin. Oncol. 2009 27 : 2766 2771.
15. de Bono JS, Scher HI, Montgomery RB et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2008 14 : 6302 6309.
16. Flaig TW, Tangen CM, Hussain MH et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J. Clin. Oncol. 2008 26 : 1532 1536.
17. Dreicer R, Magi-Galluzzi C, Zhou M et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004 63 : 1138 1142. (Pubitemid 38746819)
18. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007 110 : 1248 1254. (Pubitemid 47435595)
19. Febbo PG, Richie JP, George DJ et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin. Cancer Res. 2005 11 : 5233 5240.
20. Chi KN, Chin JL, Winquist E, Klotz L, Saad F, Gleave ME. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J. Urol. 2008 180 : 565 570.
21. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol. 2005 23 : 8253 8261.
22. Attard G, Reid AH, A'Hern R et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 2009 27 : 3742 3748.
23. Attard G, Reid AH, Yap TA et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J. Clin. Oncol. 2008 26 : 4563 4571.
24. Tran C, Ouk S, Clegg NJ et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009 324 : 787 790.
25. Scher HI, Beer T, Higano CS et al. Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC). J. Clin. Oncol. 2009 27 (15s abstract 5011.
26. Small EJ, Schellhammer PF, Higano CS et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol. 2006 24 : 3089 3094.
27. Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol. 2007 25 : 669 674.
28. Higano CS, Schellhammer PF, Small EJ et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009 115 : 3670 3679.
29. Schellhammer PF, Higano C, Berger ER et al. A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC). Late Breaking Abstract 4, American Urological Association Annual Meeting 28 April 2009, Chicago, IL.
30. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006 107 : 67 74.
31. Higano CS, Corman JM, Smith DC et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008 113 : 975 984.
32. Small E, Demkow T, Gerritsen WR et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proceedings Genitourinary Cancer Symposium February 2009, Orlando, FL, abstract 7.
33. Gerritsen W, van den Eertwegh AJ, de Gruijl T et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J. Clin. Oncol. 2008 26 : abstract 5146.
34. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2007 13 : 1810 1815.
35. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert. Opin. Investig. Drugs 2009 18 : 1001 1011.
36. Kantoff PW, Schuetz T, Blumenstein BA et al. Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 2009 27 (15s abstract 5013.
37. George DJ, Halabi S, Shepard TF et al. Prognostic significance of plasma vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B 9480. Clin. Cancer Res. 2001 7 : 1932 1936. (Pubitemid 32994827)
38. Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001 61 : 2533 2536. (Pubitemid 32685834)
39. Sonpavde G, Periman PO, Bernold D et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann. Oncol. 2009 (Epub ahead of print).
40. Dror Michaelson M, Regan MM, Oh WK et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann. Oncol. 2009 20 : 913 920.
41. George DJ, Liu G, Wilding G et al. Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary results. J. Clin. Oncol. 2008 26 : abstract 5131.
42. Chi KN, Ellard SL, Hotte SJ et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann. Oncol. 2008 19 : 746 751.
43. Dahut WL, Scripture C, Posadas E et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 2008 14 : 209 214.
44. Steinbild S, Mross K, Frost A et al. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV. Br. J. Cancer 2007 97 : 1480 1485.
45. Carducci MA, Nelson JB, Bowling MK et al. Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. 2002 20 : 2171 2180.
46. Carducci MA, Saad F, Abrahamsson PA et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007 110 : 1959 1966.
47. James ND, Caty A, Borre M et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur. Urol. 2009 55 : 1112 1123.
48. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 2004 96 : 879 882. (Pubitemid 38807610)
49. Roodman GD. Mechanisms of bone metastasis. N. Engl. J. Med. 2004 350 : 1655 1664.
50. Fizazi K, Yang J, Peleg S et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. Clin. Cancer Res. 2003 9 : 2587 2597.
51. Fizazi K, Lipton A, Mariette X et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 2009 27 : 1564 1571.
52. Picus JHS Rini B et al. The use of bevacizumab with docetaxel and estramustine in hormone refractory prostate cancer: Initial results of CALGB 90006. Proc. Am. Soc. Clin. Oncol. 2003 22 : 393 abstract 1578.
53. Ning YM, Arlen PM, Gulley JL et al. Phase II trial of thalidomide, bevacizumab, and docetaxel in patients with metastatic castration-refractory prostate cancer (CRPC). J. Clin. Oncol. 2008 26 (May 20 suppl): abstract 5000.
54. Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye. Drugs R. D. 2008 9 : 261 269.
55. Ng SS, MacPherson GR, Gutschow M, Eger K, Figg WD. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice. Clin. Cancer Res. 2004 10 : 4192 4197.
56. Figg WD, Dahut W, Duray P et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin. Cancer Res. 2001 7 : 1888 1893. (Pubitemid 32994822)
57. Dahut WL, Gulley JL, Arlen PM et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J. Clin. Oncol. 2004 22 : 2532 2539.
58. Garcia JA, Cooney MM, Elson P et al. Clinical activity of ketoconazole and lenalidomide in castrated progressive prostate carcinoma (CPPCA): Preliminary results of a phase II trial. Genitourinary Cancer Symposium 2008, San Francisco, CA: abstract 27.
59. Petrylak DP, Resto-Garces K, Tibyan M et al. A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J. Clin. Oncol. 2009 27 (15s abstract 5156.
60. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992 52 : 6940 6944.
61. Tolcher AW, Chi K, Kuhn J et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin. Cancer Res. 2005 11 : 3854 3861.
62. Sternberg CN, Dumez H, Van Poppel H et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol. 2009 20 : 1264 1269.
63. MacVicar GR, Greco A, Reeves J et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). J. Clin. Oncol. 2009 27 (15s abstract 5062.
64. Poiesz B, Reeves J, McNulty W et al. Preliminary report of an open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with docetaxel refractory prostate cancer. J. Clin. Oncol. 2009 27 (15s abstract 5145.
65. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 2005 23 : 4591 4601.
66. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 2004 22 : 2522 2531.
67. Lara PN Jr., Chee KG, Longmate J et al. Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. Cancer 2004 100 : 2125 2131. (Pubitemid 38580330)
68. de Bono JS, Bellmunt J, Attard G et al. Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer. J. Clin. Oncol. 2007 25 : 257 262.
69. Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin. Cancer Res. 2007 13 : 5834 5840.
70. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D, Ludwig DL. IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin. Cancer Res. 2007 13 : 5549s 5555s.
71. Canil CM, Moore MJ, Winquist E et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol. 2005 23 : 455 460. (Pubitemid 46224221)
72. Small EJ, Fontana J, Tannir N et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007 100 : 765 769.
73. Gravis G, Bladou F, Salem N et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann. Oncol. 2008 19 : 1624 1628.
74. Gross M, Higano C, Pantuck A et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer 2007 7 : 142.
75. Whang YE, Moore CN, Armstrong AJ et al. A phase II trial of lapatinib in hormone refractory prostate cancer. J. Clin. Oncol. 2008 26 : abstract 16037.
76. Tatarov O, Mitchell TJ, Seywright M, Leung HY, Brunton VG, Edwards J. SRC family kinase activity is up-regulated in hormone-refractory prostate cancer. Clin. Cancer Res. 2009 15 : 3540 3549.
77. Park SI, Zhang J, Phillips KA et al. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008 68 : 3323 3333.
78. Koreckij T, Nguyen H, Brown LG, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br. J. Cancer 2009 101 : 263 268.
79. Yu EY, Wilding G, Posadas E et al. Dasatinib in patients with metastatic hormone-refractory (castration-resistant) progressive prostate cancer: a phase II study. J. Clin. Oncol. 2008 26 (May 20 suppl): Abstract 5156.
80. Chi KN, Eisenhauer E, Fazli L et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Natl. Cancer Inst. 2005 97 : 1287 1296.
81. Chi KN, Siu LL, Hirte H et al. A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 2008 14 : 833 839.
82. Chi KN, Hotte SJ, Yu E et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2009 27 (15s abstract 5012.
83. Saad F, Hotte SJ, North S et al. A phase II randomized study evaluating custirsen (OGX-011) in patients with hormone refractory prostate cancer (HRPC) who relapsed on or within 6 Months of first-line docetaxel therapy. J. Clin. Oncol. 2008 26 (May 20 suppl): Abstract 5002.
84. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005 6 : 392 400.
85. Sartor O, Reid RH, Hoskin PJ et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004 63 : 940 945.
86. Tu SM, Millikan RE, Mengistu B et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001 357 : 336 341.
87. Morris MJ, Pandit-Taskar N, Carrasquillo J et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J. Clin. Oncol. 2009 27 : 2436 2442.
88. Tu SM, Mathew P, Wong FC, Jones D, Johnson MM, Logothetis CJ. Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer. J. Clin. Oncol. 2009 27 : 3319 3324.
89. Fizazi K, Beuzeboc P, Lumbroso J et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 2009 27 : 2429 2435.
90. Getzenberg RH, Light BW, Lapco PE et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997 50 : 999 1006.
91. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 2003 21 : 123 128.
92. Novacea Press Release. November 2007.
93. Carducci MA, Musib L, Kies MS et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J. Clin. Oncol. 2006 24 : 4092 4099.
94. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res. 2005 65 : 2825 2831.
95. Morgan TM, Pitts TE, Gross TS, Poliachik SL, Vessella RL, Corey E. RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid. Prostate 2008 68 : 861 871.
96. Ramachandran K, Gopisetty G, Gordian E et al. Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009 69 : 1527 1535.
97. Sonpavde G, Aparicio A, Zhan F et al. Azacitidine favorably impacts PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaive castration resistant prostate cancer. Urol. Oncol. 2009 (Epub ahead of print).